ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Belimumab in childhood systemic lupus erythematosus: A review of available data

Chen, Feng; Zheng, Ying; Chen, Xinying; Wen, Zhanfa; Xu, Youjia*; Yang, Jinghua*; Xu, Kaisi*广东省人民医院; 广州中医药大学
Frontiers in Immunology2022-7-27DOI: 10.3389/fimmu.2022.940416
4被引6阅读
引用收藏
分享

摘要

IntroductionChildhood systemic lupus erythematosus (cSLE) is a complex multisystem autoimmune disease. In 2019, belimumab was approved for the clinical treatment for cSLE, making it the only biological agent approved for cSLE children aged 5 and older in 60 years. ObjectiveTo review emerging evidence on belimumab in cSLE published up to April 2022, so as to provide information for clinical decision-making. MethodA comprehensive search of relevant publications up to the date of April 2022 in PUBMED, EMBASE, WOS, COCHRANE, ClinicalTrials.gov, CBM, CNKI and WANFANG was performed using the following criteria: (a) English and Chinese language studies; (b) RCT studies, cohort studies, or case-control studies; (c) patients with age <18; (d) Observational studies or case series studies contain more than 5 patients. All relevant literature was independently screened and reviewed by at least two reviewers and the obtained literature data were extracted and reviewed by two authors. ResultsFive publications met the inclusion/exclusion criteria for cSLE: one randomized controlled trial, one retrospective cohort study, and three case series. There was a high degree of heterogeneity among several studies, and the availability of baseline and outcome data provided was uneven. ConclusionAt present, there is a lack of high-quality clinical trials of belimumab in the treatment of cSLE. Based on the current research, it is believed that the use of belimumab can inhibit cSLE activity, reduce the dose of corticosteroids and immunosuppressants, and delay kidney damage. Also it shows clinical benefit in alleviating symptoms of monogenic cSLE refractory to standard therapy. More studies are urgently needed to validate the clinical efficacy of belimumab in cSLE and to evaluate its long-term safety in pediatric populations to promote evidence-based practice.

学科与关键词

关键词
Belimumabchildhood systemic erythematosus (cSLE)targeted therapypediatric lupusimmunology
相关
加载中…
  • Response to belimumab among patients with refractory lupus nephritis: a real-world observational retrospective multicenter study
    Zhang, Shuoyang; Qiu, Qian; Zeng, Shan; Li, Hao; Xu, Liujing; Jie, Ligang; Hu, Xuejun; Xiao, Youjun; Chen, Dongying; Zhan, Zhongping; Liang, Liuqin*; Yu, Qinghong*; Xu, Hanshi*CLINICAL RHEUMATOLOGY, 2023.
  • Efficacy and safety of belimumab in systemic lupus erythematosus patients with severe lupus nephritis requiring renal replacement therapy
    Liu, Diankun; Zhou, Qiang; Wang, Di; Qu, Yuan; Guo, Qihong; Wen, Jing; Yu, Qinghong*; Ai, Jun*Lupus, 2022, 31(12): 1456-1467.被引 1
  • Efficacy of belimumab in patients with systemic lupus erythematosus from North East Asia: Results of exploratory subgroup analyses
    Zheng, Jie; Gu, Jieruo; Su, Yin; Li, Yang; Li, Xingfu; Xiong, Cui; Cao, Hua; Quasny, Holly; Chu, Myron; Curtis, Paula; DeRose, Kathleen; Kurrasch, Regina; Meizlik, Paige; Roth, David A.; Zhang, Fengchun*Modern Rheumatology, 2023, 33(4): 751-757.被引 2
查看全部 →

发表信息

论文状态
公开发表
期刊
Frontiers in Immunology
发表日期
2022-07-27
卷期
第 13 卷
页码
940416
DOI
10.3389/fimmu.2022.940416
语言
ENGLISH
期刊等级
2区
成果收录
SCIE
资助标注
Xiaorong Luo's Renowned Expert Inheritance Studio of National Administration of Traditional Chinese Medicine; [14GG2X02]

作者

  • C

    Chen, Feng (第一作者)

    2 · guangzhou univ chinese med

  • Z

    Zheng, Ying

    2 · guangzhou univ chinese med

查看全部 7 位作者收起作者
  • C

    Chen, Xinying

    2 · guangzhou univ chinese med · guangdong prov hosp

  • W

    Wen, Zhanfa

    2 · guangzhou univ chinese med

  • X

    Xu, Youjia (通讯)

    2 · guangzhou univ chinese med · guangdong prov hosp

  • Y

    Yang, Jinghua (通讯)

    2 · guangzhou univ chinese med · guangdong prov hosp

  • X

    Xu, Kaisi (通讯)

    2 · guangzhou univ chinese med · guangdong prov hosp

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417